| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/25/2003 | US20030181406 Immunostimulants, synthetic oligonucleotide or polynucleotide for treating infectious diseases, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia |
| 09/25/2003 | US20030181401 Suppressing the high level of a blood glucose, treating diabetes by administering a mixture containing galactose, acetylneuraminic acid; Type II diabetes mellitus |
| 09/25/2003 | US20030181399 Antagonist inhibiting genetic translation of bacterial, targeting the antibiotic resist strains |
| 09/25/2003 | US20030181398 Injecting penicillins, cephalosporins, tetracyclines, erythromycins, tylosins, quinolone and other antibiotics, to skins of animals such as cattle, swine or sheep, for prophylaxis of respiratory system disorders |
| 09/25/2003 | US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof |
| 09/25/2003 | US20030181396 Novel oligospirostanoside, pharmaceutical composition containing novel oligospirostanoside and method for immunomodulation using said oligospirostanoside |
| 09/25/2003 | US20030181394 Carbobydrates such as alpha-D-galactopyranosyl-1,2-glycerol and/or isomers, obtained by solvent extraction from algae, for use as viricides or anticarcinogenic agents |
| 09/25/2003 | US20030181393 Cancer treatment including glycolytic inhibitors |
| 09/25/2003 | US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery |
| 09/25/2003 | US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 09/25/2003 | US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire |
| 09/25/2003 | US20030181384 Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| 09/25/2003 | US20030181383 Methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Trefoil peptides are administered in effective concentrations either alone or in combination with |
| 09/25/2003 | US20030181381 Factor X analogues having a modified protease cleavage site |
| 09/25/2003 | US20030181379 Novel fibroblast growth factor (FGF23) and methods for use |
| 09/25/2003 | US20030181374 Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly |
| 09/25/2003 | US20030181371 Compositions and methods of using collajolie |
| 09/25/2003 | US20030181370 H-Y antigen |
| 09/25/2003 | US20030181363 Compounds or pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease. |
| 09/25/2003 | US20030181359 Tripeptide prodrug compounds |
| 09/25/2003 | US20030181356 Treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. The invention features a pharmaceutically acceptable composition comprising lipid for |
| 09/25/2003 | US20030181355 Inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein. |
| 09/25/2003 | US20030181354 Method for central nervous system targeting through the ocular route of drug delivery |
| 09/25/2003 | US20030181353 Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| 09/25/2003 | US20030181352 Substituted heterocyclic compounds |
| 09/25/2003 | US20030180924 Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators |
| 09/25/2003 | US20030180893 Biotransformation of biologically active compounds made of various classes of chemical substance by means of laccase and manganese peroxidase enzymes |
| 09/25/2003 | US20030180818 Isolated nucleic acid molecules encoding human peptidoglycan recognition protein-related proteins, referred to PGRP-K (keratinocytes), PGRP-W (wound healing) and PGRP-C (chondrosarcoma) |
| 09/25/2003 | US20030180804 (Serine) protease modulators; membrane proteins |
| 09/25/2003 | US20030180785 Polynucleotide molecules encoding Neospora proteins |
| 09/25/2003 | US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3 |
| 09/25/2003 | US20030180770 Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
| 09/25/2003 | US20030180767 ((2,2'-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2 -pyridyl) pyrazine) Os(2,2'-bipyridine)2)(X)5, where X is a counterion selected from PF6-, CL-, BR-, CF3SO3- and BF4- a supramolecular metal complex; photodynamic therapy |
| 09/25/2003 | US20030180759 Antigen derived from the gp160 env precursor protein (glycoprotein120 envelop protein)of a HIV-1 group O strain contains an amino acid sequence characterized by the fact that it reacts with antibodies raised against such antigen |
| 09/25/2003 | US20030180755 Pharmaceutical compositions in particulate form |
| 09/25/2003 | US20030180752 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/25/2003 | US20030180744 High affinity oligonucleotide ligands to growth factors |
| 09/25/2003 | US20030180734 Peptide nucleic acids |
| 09/25/2003 | US20030180719 Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
| 09/25/2003 | US20030180406 Treatment of diseases involving defective gap junctional communication |
| 09/25/2003 | US20030180405 For cosmstics, drugs; antiinflamamtory agents; oxidation resistance |
| 09/25/2003 | US20030180404 Methods of treating clinical diseases with isoflavones |
| 09/25/2003 | US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
| 09/25/2003 | US20030180396 Central nervous system disorders; screening for allergens |
| 09/25/2003 | US20030180393 Cleaning digestion tracks |
| 09/25/2003 | US20030180391 Berberine, baicalein; plant extracts; side effect reduction |
| 09/25/2003 | US20030180389 Effervescent glucosamine, chondroitin and MSM formula |
| 09/25/2003 | US20030180388 Side effect reduction; administering sodium selenite and,or amifostine |
| 09/25/2003 | US20030180383 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 09/25/2003 | US20030180382 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 09/25/2003 | US20030180381 Cobalt compound; therapy for Cmpylobacter |
| 09/25/2003 | US20030180379 Microbiocides; anticancer agents; bactericides; antiinflammatory agents; fungicides; viricides |
| 09/25/2003 | US20030180378 Dry powders of metal-containing compounds |
| 09/25/2003 | US20030180366 Bioadhesive drug delivery system |
| 09/25/2003 | US20030180363 Biodegradation polymer; liquid phase polyoxyethylene glycol |
| 09/25/2003 | US20030180362 Multi-stage oral drug controlled-release system |
| 09/25/2003 | US20030180361 Opioids; analgesics; solid dosage form; sustained release |
| 09/25/2003 | US20030180360 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene |
| 09/25/2003 | US20030180359 Controlled release |
| 09/25/2003 | US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet |
| 09/25/2003 | US20030180356 Hormone replacement therapy; compressed blend |
| 09/25/2003 | US20030180355 Combination therapy for hypertension |
| 09/25/2003 | US20030180353 Mixture of levothyroxine sodium and liothyronine sodium |
| 09/25/2003 | US20030180350 Combination compositions |
| 09/25/2003 | US20030180349 Administering before or after onset of disease |
| 09/25/2003 | US20030180345 Antidiabetic agents; administering mixture of amino acid and carrier |
| 09/25/2003 | US20030180337 Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals |
| 09/25/2003 | US20030180332 Novel pharmaceutical composition |
| 09/25/2003 | US20030180331 Facilitation of wound healing with CM101/GBS toxin |
| 09/25/2003 | US20030180328 Forming vaccines; analyzing hemagglutinin, calibration |
| 09/25/2003 | US20030180317 Diagnosis ear infections in children |
| 09/25/2003 | US20030180301 Prevention organ rejection; induction immunology response; reduce fibrosis |
| 09/25/2003 | US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation |
| 09/25/2003 | US20030180294 Administering vascular endothelial growth factor receptor inhibitor; supression lymphangiogenesis |
| 09/25/2003 | US20030180292 Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| 09/25/2003 | US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 09/25/2003 | US20030180285 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti hsp90 antibodies |
| 09/25/2003 | US20030180282 Method of treatment of thrombotic events |
| 09/25/2003 | US20030180278 Mixture containing ubiquinone compound |
| 09/25/2003 | US20030180257 Alphavirus vectors for paramyxovirus vaccines |
| 09/25/2003 | US20030180250 Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents |
| 09/25/2003 | US20030180249 Storage stability; mixture containing ion exchange resin |
| 09/25/2003 | US20030180246 Free-flowing anionic surfactant, alkanolamide and electrolytemixture |
| 09/25/2003 | US20030180237 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances |
| 09/25/2003 | US20030180236 Resorcinol derivatives |
| 09/25/2003 | US20030180230 UV-photostabilized sunscreen compositions comprising dibenzoylmethane/triazine/benzophenone compounds |
| 09/25/2003 | US20030180228 Aerosol container for formulations of salmeterol xinafoate |
| 09/25/2003 | US20030180227 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 09/25/2003 | US20030180224 Photosensitisers |
| 09/25/2003 | US20030178022 Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators |
| 09/25/2003 | DE20311240U1 Composition for promoting mental power, comprises combination of L-leucine, L-valine, L-isoleucine, L-arginine, L-aspartic acid, choline and phenylalanine |
| 09/25/2003 | CA2828595A1 Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure |
| 09/25/2003 | CA2748620A1 Naltrexone hydrochloride compositions |
| 09/25/2003 | CA2518794A1 Compositions and methods for treating emphysema |
| 09/25/2003 | CA2479676A1 Dexanabinol and dexanabinol analogs regulate inflammation related genes |
| 09/25/2003 | CA2479620A1 Ethane-1,2-diamino-bis[2r)-2-bromo-3-phenylpropanoate], method for production and use thereof |
| 09/25/2003 | CA2479481A1 Therapeutic ion channel blocking agents and methods of use thereof |
| 09/25/2003 | CA2479354A1 Broad-spectrum cephem compounds |
| 09/25/2003 | CA2479350A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| 09/25/2003 | CA2479295A1 Progesterone oral drug delivery system |